Related Experiment Video
Updated: Jan 27, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Combination therapy for patients with Type 2 diabetes: repaglinide in combination with metformin
1a Clinical Trial and Research Unit, South Eastern Sydney and Illawarra Area Health Service, PO Box W58, Wollongong West, NSW, 2500, Australia. robert.moses@sesiahs.health.nsw.gov.au.
Abstract:
In patients with Type 2 diabetes mellitus (T2DM), adequate glycemic control is a critical factor in reducing long-term micro- and macro-vascular complications. Traditionally, the approach is to initiate monotherapy first, followed by combination therapy that targets two main defects in T2DM. Repaglinide, a rapidly acting insulin secretagog, stimulates insulin secretion via closure of ATP-dependent potassium channels on the cell membrane of β-cells. Repaglinide is ideally used at mealtime to reduce postprandial glucose levels, thus lowering the 24-h blood glucose profile and improving HbA1c levels. Metformin is an insulin sensitizer that effectively acts against insulin resistance, one of the predominant metabolic defects in T2DM. A combination of repaglinide and metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. When monotherapy with oral antidiabetic agents fails, combination therapy with repaglinide plus metformin has been demonstrated to be safe and effective in the treatment of T2DM.
Insights
Repaglinide and metformin combination therapy improves glycemic control in Type 2 diabetes mellitus (T2DM) when monotherapy is insufficient. This safe and effective treatment aids in managing blood glucose levels and reducing long-term complications.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) management requires adequate glycemic control to prevent micro- and macro-vascular complications.
- Traditional T2DM treatment involves monotherapy followed by combination therapy targeting key defects.
- Insulin resistance and impaired insulin secretion are primary defects in T2DM.
Purpose of the Study:
- To evaluate the efficacy and safety of repaglinide plus metformin combination therapy in T2DM patients.
- To assess the role of this combination as an adjunct to diet and exercise.
- To determine the effectiveness of this combination when oral antidiabetic monotherapy fails.
Main Methods:
- Repaglinide, a mealtime insulin secretagogue, reduces postprandial glucose.
- Metformin, an insulin sensitizer, addresses insulin resistance.
- Combination therapy integrates these agents to target multiple T2DM defects.
Main Results:
- Repaglinide and metformin combination therapy improves 24-hour glucose profiles and HbA1c levels.
- This combination is safe and effective for T2DM patients.
- It demonstrates significant benefits when monotherapy is inadequate.
Conclusions:
- Combination therapy with repaglinide and metformin is a valuable treatment option for T2DM.
- It effectively improves glycemic control in adults with T2DM.
- This approach is indicated as an adjunct to diet and exercise for better T2DM management.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Diabetes Mellitus: Type 2 and Gestational
Impedance Combination
Combination Of Resistors
Stresses under Combined Loadings
The process begins by slicing the tube at critical points and analyzing the internal forces and stress components at these sections, focusing on the centroid. Normal stresses, generated by axial forces and bending moments, are either compressive or tensile and vary across the section from...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

